OmniAb (OABI) stock

Antibody discovery , market cap $760M

Antibody discovery

Market cap $760M

$5.09

-0.39%

After-hours $5.09 0.00%

As of 6:23 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

Above Average

In its industry

#21of 291

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-6.3%

Above the 200-day

OABI's Quality Score fell 1 point on Mon, Nov 2, to 14.

See OABI's 14 chart checksSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is OABI up?

Up 243% in a year while the S&P 500 rose 12%.

Its filed figures weakened while the shares beat the market.

Sources: Price history, Oct 30, 2026; Quarterly reports, Jun 30, 2026

1 more reason, free with an account →The other side, how the business stands, and the timeline, for Pro members.

Key facts on OABI

Key facts on OABI
The company	Sales up 67% on the year
Latest filing	8-K, Oct 30 Reported its quarterly results

1 more reason behind OABI's 14, free with an account →6 more reasons behind OABI's 14, for Pro members.

OABI in the news

Fri Oct 30OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights SEC filing 7:42 AM ET · Business Wire OABI closed −2.3% that day.

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

3 more dates ahead: conferences, for Pro members.

OABI catalysts

Coming up

After its last 4 reports it closed +14.7% on average, higher 3 of 4 times.

2 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

Why OABI scores 14

Above Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means

+7Chart checks 7 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Persistence adds
News adds

No effect today: Size and Profit.

What every line is worth, and the reason behind it, on OABI and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 6:23 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when OABI's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on OABI and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

OABI has 7 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on OABI, and all 14 on every stock.Get in free →

OABI RSI today: 58.1, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1458.1
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 3 sessions ago.
50-day average$4.67
The price is 9.0% above it.
200-day average$2.72
The price is 87.1% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jun 1.
ADX 1424.0
Under 25, with +DI below -DI.
Support$4.50
Swing low from Oct 16, 11.5% below the price.
Resistance$5.43
Swing high from Sep 2, 6.7% above the price.
52-week high$5.43
From Sep 2, 6.7% above the price.
52-week low$1.30
From Nov 5, 2025, 74.5% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $4.32 to $5.27.
Volume1.6x
Against its 20-day average, for the time of day.

The deep dive on OABI

What it does and how it makes money7 findingsLicense And Milestone Revenue made up 52% of its revenue in fiscal 2025 ($9.77M of $18.7M), against 53% in fiscal 2024; services 39%.SEC filing · Mar 4, 2026"The patents and applications in our portfolio are expected to expire between 2029 and 2034, without accounting for potentially available patent term adjustments and extensions or disclaimers." (10-K for fiscal 2025)SEC filing · Mar 4, 2026
What changed in its filings1 findingOne partner made up 15% of its revenue in fiscal 2025, up from 12% in fiscal 2024.SEC filing · Mar 4, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades OABI, for Pro members

6 more findings on OABI, each with its source, for Pro membersGet in free →

How OABI ranks in Biotech

OABI is #21 of 291 by Quality Score.

How OABI ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	NUVBNuvation Bio		Open for its score
	NVAXNovavax		Open for its score
	OCULOcular Therapeutix		Open for its score
	OKUROnKure Therapeutics		Open for its score
21	OABIOmniAb	7/14	14

When does OABI report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 122 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What OABI reported on Oct 30, 2026

The quarter

Sales of $4.0M, 78% more than a year ago; a loss of $0.12 a share, from $0.14.

“Revenue for the third quarter of 2026 was $4.0 million, compared with $2.2 million in the prior-year period, with the increase driven primarily by service revenue and xPloration revenue.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

OABI's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Revenue	$35M to $39Mraised

Figures as filed (SEC filing, Oct 30)

5 more outlook lines, for Pro members.

In the company's words

“OmniAb expects xPloration revenue in 2026 to be between $2 million and $3 million and expects xPloration revenue to double in 2027 and to double again in 2028.”

From its results filing (SEC filing · Oct 30)

The numbers

Market value: $760M; today
Sales: $38.5M; up 67% on the year
Free cash flow: -$18.1M; last 12 months

Sales fell 32% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 10% a year over 3 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on OABI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+12.9%+37.5%-2.3%

May 7Aug 6Oct 30

Reported	When	Gap	Reaction	5 sessions
Oct 30, 2026Before open	Before open	-15.9%	-2.3%	open
Aug 6, 2026After close	After close	+5.8%	+37.5%	+53.1%
May 7, 2026After close	After close	+4.8%	+12.9%	+49.0%

OABI closed higher after 3 of its last 4 reports.

All 4 reports, and OABI's Quality Score going into each

OABI sales and profit by year

Sales and profit by year

Sales grew in one of the last four years, to $18.7M in 2025. It lost money in each of the five years.

OABI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Matthew W. FoehrPresident and CEO · 4 trades
Kurt A. GustafsonExecutive VP, Finance and CFO · 4 trades
Charles S. BerkmanChief Legal Officer · 4 trades
John L. HigginsDirector · 2 trades
Carolyn R. BertozziDirector
Jennifer R. CochranDirector
Philip J. GotwalsDirector
Steven C. CrouseDirector

One more officer or director files at OABI. Each page above names the rest.

See insider trades by person

About OmniAb

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

89 employeesEmeryville, CAomniab.com

What OmniAb says it competes with

“The market for technologies that enable the discovery and development of therapeutic antibodies, such as ours, is global, characterized by intense competition and subject to significant intellectual property barriers.”

From its annual report, SEC filing · Mar 4, 2026

2 more sentences and what it says it does, for Pro membersGet in free →

OABI's score card

OmniAb (OABI): Quality Score 14, Above Average, #21 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move OABI's score: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

See OABI's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: OABI's Quality Score is 14 (Above Average), #21 of 291 in Biotech.

Is OABI a good stock to buy? What its Quality Score says

OABI scores 14 today, which Breakaway calls Above Average. It is #21 of 291 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 243% in a year while the S&P 500 rose 12%. Shares: 21.3% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OABI's Quality Score?

OABI scores 14 today, which Breakaway calls Above Average (11 to 14). That is #21 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OABI's 14.

When does OABI report earnings?

Expected to report Thu Mar 4, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. OABI closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.